[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595577":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":19,"responsibleParty":29,"collaborators":19,"id":31,"slug":19,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":34,"acronym":19,"eligibilityCriteria":35,"healthyVolunteers":32,"sex":36,"minAge":37,"maxAge":19,"enrollmentInfo":38,"targetDuration":19,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":47,"overallStatus":49,"whyStopped":19,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":19},{"fullName":5,"class":6},"University of Chicago","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Blinded Continuous Glucose Monitoring Device","EXPERIMENTAL","Subjects will wear a blinded continuous glucose monitoring device.",[13],"Device: Blinded Continuous Glucose Monitoring Device",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DEVICE","Subjects will be asked to wear blinded continuous glucose monitoring device for 14 days.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Laura Dickens, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","773-795-0460","ldickens1@bsd.uchicago.edu",{"type":30,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100595577",false,"NCT07034261","Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes","Inclusion Criteria:\n\n1. Age greater than or equal to 18\n2. Completed pregnancy with delivery of a live born infant(s). Pregnancies with multiple gestations will be included\n3. No prior history of type 1 or type 2 diabetes\n\n   \\* Patients with a history of gestational diabetes (GDM) in a prior pregnancy will be eligible for inclusion.\n4. GDM diagnosis by standard screening at 24-28 weeks\n\n   * 2 hour 75g oral glucose tolerance test (OGTT); one abnormal value required for diagnosis\n\n     * Fasting glucose 92\n     * 1 hour 180\n     * 2 hour 153\n   * 3 hour 100g OGTT - two abnormal values required for diagnosis\n\n     * Fasting glucose - 95\n     * 1 hour 180\n     * 2 hour 155\n     * 3 hour 140\n\nThere are no exclusion criteria for this study. Eligibility will be based on inclusion criteria.","FEMALE","18 Years",{"count":39,"type":40},50,"ESTIMATED","INTERVENTIONAL",[43],"NA","The aim of this study is to determine the ability of postpartum continuous glucose monitoring (CGM) for subjects with gestational diabetes (GDM) to predict dysglycemia on 4-12 week postpartum oral glucose tolerance test (OGTT).",[46],"Gestational Diabetes",[48],"CGM Device","NOT_YET_RECRUITING","2026-06-08",{"date":52,"type":53},"2026-06-11","ACTUAL",{"date":55,"type":40},"2026-09",{"date":57,"type":40},"2027-09",{"name":5,"class":6}]